Drugs / IPN60300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07213817 | Dec 2025 → Oct 2028 expected | metastatic neoplasm | Ipsen | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Ipsen | Results Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR ipsen.com ↗
Preclinical findings showed pronounced over-expression of ITGA2 across multiple solid tumors—including pancreatic, gastric and colorectal cancers—with clear differential expression when compared to normal tissues. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Ipsen | Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR ipsen.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPN60300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07213817 ↗ |